Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
Ormhøj M, Scarfò I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA, Castano AP, Larson RC, Riley LS, Schmidts A, Choi BD, Andersen RS, Cédile O, Nyvold CG, Christensen JH, Gjerstorff MF, Ditzel HJ, Weinstock DM, Barington T, Frigault MJ, Maus MV. Ormhøj M, et al. Among authors: schmidts a. Clin Cancer Res. 2024 May 15;30(10):2286. doi: 10.1158/1078-0432.CCR-24-1059. Clin Cancer Res. 2024. PMID: 38745479 No abstract available.
Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma.
Schmidts A, Srivastava AA, Ramapriyan R, Bailey SR, Bouffard AA, Cahill DP, Carter BS, Curry WT, Dunn GP, Frigault MJ, Gerstner ER, Ghannam JY, Kann MC, Larson RC, Leick MB, Nahed BV, Richardson LG, Scarfò I, Sun J, Wakimoto H, Maus MV, Choi BD. Schmidts A, et al. Neurooncol Adv. 2022 Dec 22;5(1):vdac185. doi: 10.1093/noajnl/vdac185. eCollection 2023 Jan-Dec. Neurooncol Adv. 2022. PMID: 36751672 Free PMC article.
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies.
Frigault MJ, Graham CE, Berger TR, Ritchey J, Horick NK, El-Jawahri A, Scarfò I, Schmidts A, Haradhvala NJ, Wehrli M, Lee WH, Parker AL, Wiggin HR, Bouffard A, Dey A, Leick MB, Katsis K, Elder EL, Dolaher MA, Cook DT, Chekmasova AA, Huang L, Nikiforow S, Daley H, Ritz J, Armant M, Preffer F, DiPersio JF, Nardi V, Chen YB, Gallagher KME, Maus MV. Frigault MJ, et al. Among authors: schmidts a. Blood. 2024 Sep 12;144(11):1153-1167. doi: 10.1182/blood.2024024104. Blood. 2024. PMID: 38781564 Clinical Trial.
Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
Wehrli M, Guinn S, Birocchi F, Kuo A, Sun Y, Larson RC, Almazan AJ, Scarfò I, Bouffard AA, Bailey SR, Anekal PV, Montero Llopis P, Nieman LT, Song Y, Xu KH, Berger TR, Kann MC, Leick MB, Silva H, Salas-Benito D, Kienka T, Grauwet K, Armstrong TD, Zhang R, Zhu Q, Fu J, Schmidts A, Korell F, Jan M, Choi BD, Liss AS, Boland GM, Ting DT, Burkhart RA, Jenkins RW, Zheng L, Jaffee EM, Zimmerman JW, Maus MV. Wehrli M, et al. Among authors: schmidts a. Clin Cancer Res. 2024 May 1;30(9):1859-1877. doi: 10.1158/1078-0432.CCR-23-3841. Clin Cancer Res. 2024. PMID: 38393682 Free PMC article.
A gentler yield of ex vivo-edited T cells.
Grünewald J, Schmidts A. Grünewald J, et al. Among authors: schmidts a. Nat Biomed Eng. 2023 May;7(5):607-608. doi: 10.1038/s41551-023-01042-0. Nat Biomed Eng. 2023. PMID: 37208465 No abstract available.
Peritransplant CAR-T cells.
Schmidts A. Schmidts A. Blood. 2023 Feb 9;141(6):564-566. doi: 10.1182/blood.2022018584. Blood. 2023. PMID: 36757730 Free article. No abstract available.
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia.
Leick MB, Silva H, Scarfò I, Larson R, Choi BD, Bouffard AA, Gallagher K, Schmidts A, Bailey SR, Kann MC, Jan M, Wehrli M, Grauwet K, Horick N, Frigault MJ, Maus MV. Leick MB, et al. Among authors: schmidts a. Cancer Cell. 2022 May 9;40(5):494-508.e5. doi: 10.1016/j.ccell.2022.04.001. Epub 2022 Apr 21. Cancer Cell. 2022. PMID: 35452603 Free PMC article.
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours.
Larson RC, Kann MC, Bailey SR, Haradhvala NJ, Llopis PM, Bouffard AA, Scarfó I, Leick MB, Grauwet K, Berger TR, Stewart K, Anekal PV, Jan M, Joung J, Schmidts A, Ouspenskaia T, Law T, Regev A, Getz G, Maus MV. Larson RC, et al. Among authors: schmidts a. Nature. 2022 Apr;604(7906):563-570. doi: 10.1038/s41586-022-04585-5. Epub 2022 Apr 13. Nature. 2022. PMID: 35418687
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.
Bailey SR, Vatsa S, Larson RC, Bouffard AA, Scarfò I, Kann MC, Berger TR, Leick MB, Wehrli M, Schmidts A, Silva H, Lindell KA, Demato A, Gallagher KME, Frigault MJ, Maus MV. Bailey SR, et al. Among authors: schmidts a. Blood Cancer Discov. 2022 Mar 1;3(2):136-153. doi: 10.1158/2643-3230.BCD-21-0181. Blood Cancer Discov. 2022. PMID: 35015685 Free PMC article.
31 results